Clinical trials: Metformin
Erythroplakia, Hyperplasia
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia).
- Conditions
- Erythroplakia, Hyperplasia, Oral Cavity Carcinoma, Oral Leukoplakia
- Trial name
- NCT02581137
- Testing
- Laboratory Biomarker Analysis, Metformin Hydrochloride
- Where
- 4 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Type 2 Diabetes Mellitus
MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes).
- Trial name
- NCT00103857
- Testing
- Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Comparator: MK0431 100 mg q.d. (q.d. = once daily), Comparator: Metformin 500 mg b.i.d.
- Volunteers
- 1,208 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Colesevelam for Children With Type 2 Diabetes
This study will evaluate the efficacy and safety of the study drug in treating type 2 diabetes in children 10 to 17 years old. The groups will be low-dose (0.625 g Welchol) and high-dose (3.75 g Welchol).
- Trial name
- WELKid DM (NCT01258075)
- Testing
- High-dose colesevelam, Low-dose colesevelam
- Where
- 24 sites in United States
- Volunteers
- 236 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator
This is a 24 week study comparing the efficacy of four dose levels of INT131 besylate with pioglitazone HCl in patients with type 2 diabetes.
- Trial name
- NCT00631007
- Testing
- INT131 besylate, Pioglitazone HCl
- Where
- 66 sites in United States, Mexico
- Volunteers
- 367 people
- Sponsor
- InteKrin Therapeutics, Inc.
Diabetes Mellitus, Dyslipidemias
Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.
The purpose of this study is to compare pioglitazone and metformin combination therapy, twice daily (BID), to glimepiride and metformin combination therapy for treating diabetic subjects with dyslipidemia.
- Trial name
- NCT00770653
- Testing
- Pioglitazone and Metformin, Glimepiride and Metformin
- Where
- 64 sites in Germany
- Volunteers
- 305 people
- Sponsor
- Takeda
Diabetes Mellitus
Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.
The purpose of this study is to determine the safety and efficacy of alogliptin, once daily (QD), compared to diet and exercise, sulfonylurea, metformin and a combination of sulfonylurea and metformin for treating subjects with…
- Trial name
- NCT00755846
- Testing
- Alogliptin
- Volunteers
- 265 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-F1 (NCT00763451)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Healthy
Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets
The primary objective of this trial is to establish bioequivalence of two fixed dose combination (FDC) tablets (containing medium dose empagliflozin/500 mg metformin [Test 1] and low dose empagliflozin/500 mg metformin [Test 2])…
- Trial name
- NCT01844531
- Testing
- empagliflozin, metformin (Glucophage®), empagliflozin and metformin
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Non Insulin Dependent Diabetes, Pregnancy
Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes
Many women come into pregnancy with diabetes that is controlled with either Metformin or diet control; however, the current standard of care for the treatment of preexisting diabetes in pregnancy is insulin.
- Trial name
- MIPOD (NCT00835861)
- Testing
- Metformin, Insulin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of North Carolina, Chapel Hill
Diabetes Mellitus, Type 2
Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes
The objective of the study is to investigate the efficacy and safety of linagliptin 2.5 mg twice daily compared to 5 mg once daily compared to placebo given orally for 12 weeks as add-on therapy to metformin in patients with type…
- Trial name
- NCT01012037
- Testing
- linagliptin low dose, linagliptin medium dose
- Where
- 84 sites in Belgium, Canada and 7 more
- Volunteers
- 491 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin detemir plus insulin aspart and NPH insulin plus human soluble insulin both in a basal bolus regimen with or without metformin in…
- Trial name
- NCT01486966
- Testing
- insulin detemir, insulin aspart, insulin NPH
- Where
- 6 sites in China
- Volunteers
- 58 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes
This study in Germany is designed to compare the effects of twice-daily exenatide plus metformin and twice-daily premixed human insulin aspart plus metformin with respect to glycemic control, as measured by HbA1c, combined with…
- Trial name
- NCT00434954
- Testing
- exenatide twice daily (BID), premixed insulin aspart twice daily (BID)
- Where
- 39 sites in Germany
- Volunteers
- 494 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
The purpose of this study is to investigate the effect of bexagliflozin compared to glimepiride as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02769481
- Testing
- Bexagliflozin, Glimepiride
- Where
- 45 sites in United States, Germany and 2 more
- Volunteers
- 426 people
- Sponsor
- Theracos
Type II Diabetes, Nonalcoholic Fatty Liver
Fatty Liver Study in Patients With Type II Diabetes
The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with…
- Trial name
- NCT02365233
- Testing
- DPP4 inhibitor, Pioglitazone, Lantus insulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Diabetes Mellitus
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR
The purpose of this study is to demonstrate bioequivalence (BE) of a 5 mg saxagliptin/1000 mg metformin extended release (XR) fixed-dose combination (FDC) tablet (manufactured in Mt Vernon, Indiana) relative to a coadministered 5…
- Trial name
- NCT01192152
- Testing
- saxagliptin, Glucophage XR, saxagliptin + metformin XR (FDC tablet)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Metformin ER 750 mg Tablets, Fasting
The objective of this study is to compare the rate and extent of absorption of metformin from a test formulation of Metformin ER 750 mg Tablets versus the reference Glucophage® XR 750 mg Tablets under fasting conditions.
- Trial name
- NCT00834743
- Testing
- Glucophage® XR 750 mg Tablets, Metformin ER 750 mg Tablets
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Diabetes Mellitus, Type 2
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
This multicenter, randomized, double-blind, placebo controlled, parallel group study is being conducted to provide data on efficacy, safety, tolerability and pharmacokinetics (PK) of multiple dose levels of PF-06882961 in adults…
- Trial name
- NCT03985293
- Testing
- PF-06882961
- Where
- 83 sites in United States, Bulgaria and 6 more
- Volunteers
- 412 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
The hypothesis of this Phase 2, 12-week study, is that DS-8500a will improve glycemic control relative to placebo, based on changes in HbA1c, with acceptable safety and tolerability, in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT02647320
- Testing
- Sitagliptin 100 mg, DS-8500a 25mg
- Where
- 58 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer
The goal of this clinical research study is to learn if metformin can help to control nerve damage (loss of motor or sensory function) that may be caused by treatment with paclitaxel in patients with breast cancer.
- Trial name
- NCT02360059
- Testing
- Metformin, Questionnaires, Sensory and Fine-Motor Tests
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B-Cell Lymphoma
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
Evaluation of impact of metformin on 2 year progression-free survival (PFS) rate in subjects with previously untreated DLBCL when added to standard induction therapy. (R-CHOP)
- Trial name
- DLBCL (NCT02531308)
- Testing
- Metformin, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Rush University Medical Center